COL6A1 and myopathy: In conclusion, our data in col6a1−/− animals point at spermidine as a nutraceutical therapeutic option for COL6-related myopathies and indicate that this approach is valuable for the design of novel treatments, with spermidine alone or in combination with other strategies, and their translation into clinical trials.